Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer

INTRODUCTION: In regards to resectable muscle-invasive bladder cancer (MIBC) patients, contemporary guidelines recommend treatment with radical cystectomy and perioperative chemotherapy (neoadjuvant or adjuvant). In addition, the 5-year survival rate ranges from 36% to 48% in connection to T3 or T4...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawasdee, Anupong, Tanthanuch, Monthira, Bejrananda, Tanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930955/
https://www.ncbi.nlm.nih.gov/pubmed/36444575
http://dx.doi.org/10.31557/APJCP.2022.23.11.3641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930955/
https://www.ncbi.nlm.nih.gov/pubmed/36444575
http://dx.doi.org/10.31557/APJCP.2022.23.11.3641

Ejemplares similares